Lynparza
Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead
Anika Sharma
Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...
Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)
Anika Sharma
ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...
Legal Skirmishes Erupt as AstraZeneca Delves into Battle Over Drug Pricing Reforms with IRA
Anika Sharma
As the clock ticks down to the eagerly awaited unveiling of the Centers for Medicare and Medicaid Services’ (CMS) list ...
